Cleveland Clinic Quantum Computing
Cleveland Clinic has formally announced the 2026 cohort of its Quantum Innovation Catalyzer Program, further solidifying its place at the forefront of medical technology. Three innovative organizations have been chosen to take advantage of IBM Quantum System One, the world’s first quantum computer devoted solely to healthcare and life sciences research, as part of this fiercely competitive program that aims to enable start-up businesses to carry out ground-breaking research.
Launched in 2023, the program offers a 12-month immersion exposure to venture-stage and early-stage organizations. The Catalyzer Program connects theoretical quantum physics to clinical applications by providing advanced technology and experienced advice from Cleveland Clinic experts.
You can also read Infleqtion Revenue Hits $32.5M in 2025, With 2026 $40M Goal
A New Frontier for Start-Up Innovation
The 2026 recipients come from varied backgrounds and research fields but have a goal: curing some of medicine’s most difficult problems. Singularity Quantum, Polaris Quantum Biotech, and EntangleBio are among this year’s cohort.
EntangleBio, a U.S.-based company with a global workforce spread throughout the U.S. and Europe, is poised to lead the way in a sector they refer to as “quantum network medicine”. The identification and management of uncommon genetic illnesses is the main emphasis of their endeavor. EntangleBio intends to investigate “genetic variants that are not harmful on their own, but cause disease when they interact” using quantum computing, in contrast to conventional approaches that frequently focus on individual genetic changes. For patients who now have few options, this strategy could greatly enhance drug repurposing efforts and open up new therapeutic targets.
Polaris Quantum Biotech, based in North Carolina, offers the experience of having created the first drug-discovery platform using quantum computers. The prediction of drug toxicity is a significant “bottleneck in modern drug discovery” that their project seeks to address. Polaris plans to improve AI models’ capacity to forecast Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) qualities by creating a Quantum Machine Learning (QML) suite.
Singularity Quantum Inc., the third recipient, has operations in Maryland, California, and Seoul, South Korea. Quantum-enhanced biomechanical modeling is the main area of study. Quantum algorithms are being developed to forecast cardiovascular risk in real time from imaging data like coronary insights. The team intends to expand this paradigm to tumor microcirculation and drug-delivery dynamics, potentially transforming precision oncology. This technique is not just for heart health.
You can also read NASA and Infleqtion News: Advancing Quantum Sensing in Orbit
Strategic Support and Global Collaboration
Given the high stakes associated with quantum research, these companies have a stringent selection process. “This unique program helps us connect with companies that have the potential to shape the future of healthcare through advanced computational methods,” said Lara Jehi, M.D., Chief Research Information Officer at Cleveland Clinic. The objective, she underlined, is to create a “quantum computing ecosystem” that helps people everywhere.
In addition to technical access, there is significant financial and cooperative support. The K5 Tokyo Black Fund will invest up to $250,000 in this year’s winners, along with an in-kind match from Cleveland Clinic. Supporting “ambitious, forward-looking innovation that can unlock meaningful advances in healthcare” excites Keenan Rice, General Partner at K5 Global.
The initiative is a crucial aspect of the Cleveland Clinic-IBM Discovery Accelerator, a ten-year collaboration devoted to developing cutting-edge biomedical applications of advanced computing.
You can also read SuperQ to Anchor BC Pavilion at Web Summit Vancouver 2026
Building on a Legacy of Success
The 2026 class continues the tradition of the first 2024–2025 class, which included Finland-based Algorithmiq and Ohio-based Qradle. These prior participants’ achievements demonstrate the program’s effectiveness.
As one of just six teams chosen from more than 200 applications, Algorithmiq has already received financing through all three stages of Wellcome Leap’s Quantum for Bio Challenge, an international project. They are investigating the potential of quantum computing to aid in the development of photon-activated cancer medications.
Qradle’s art is perhaps even more remarkable. The researchers effectively showed an end-to-end pipeline for protein folding structure prediction on actual quantum hardware in partnership with Feixiong Cheng, Ph.D. of Cleveland Clinic. Surprisingly, their findings demonstrated that quantum technology can offer a useful edge in biologically relevant predictions, surpassing the accuracy of AlphaFold 3, a top classical deep learning method.
You can also read Terra Quantum Company Go Public with $3.25B SPAC Merger
The Future of Quantum Healthcare
The medical community is keeping a close eye on these three new businesses as they embark on their 12-month adventure. At the Cleveland Clinic Main Campus, research into integrating quantum computing into clinical workflow from forecasting heart attacks to figuring out the etiology of uncommon diseases is now an ongoing endeavor.
The outcomes of earlier cohorts and the ambitious initiatives of the 2026 grantees indicate that the “quantum ecosystem” Cleveland Clinic envisioned is quickly coming to pass, even though quantum computing is still a developing science. The Quantum Innovation Catalyzer Program is laying the groundwork for the next wave of life-saving medical discoveries by fusing the most cutting-edge computing power in the world with top-notch clinical knowledge.
You can also read Xanadu 2025 Full Year Results And Public Listing Analysis
